Page last updated: 2024-08-21

diphenylamine and pf 00299804

diphenylamine has been researched along with pf 00299804 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Beijnen, JH; Bernards, R; de Vos, FYFL; Devriese, LA; Eskens, FALM; Huijberts, SCFA; Huitema, ADR; Lolkema, MPJK; Marchetti, S; Monkhorst, K; Opdam, FL; Rosing, H; Schellens, JHM; Steeghs, N; Thijssen, B; van Brummelen, EMJ; van Geel, RMJM1

Trials

1 trial(s) available for diphenylamine and pf 00299804

ArticleYear
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
    British journal of cancer, 2020, Volume: 122, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diphenylamine; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasms; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolinones

2020
chemdatabank.com